Novo Nordisk's Weight Loss Drug Wegovy In Short Supply, Yet Goes Ahead With UK Launch
Portfolio Pulse from Vandana Singh
Novo Nordisk has launched its weight loss drug Wegovy in the UK, despite acknowledging ongoing supply constraints. The drug is available through the NHS weight management scheme and in the private market. The company is working to persuade European governments and insurers to reimburse Wegovy. In the US, Wegovy is priced at $1,350 per month, while in Europe, it retails for approximately €170-€300 per month. British insurers have indicated that they will not cover Wegovy under their policies.
September 05, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Novo Nordisk's launch of Wegovy in the UK could potentially increase its revenues, but supply constraints and lack of insurance coverage could limit its market penetration.
The launch of Wegovy in the UK expands Novo Nordisk's market, potentially increasing its revenues. However, the company acknowledges supply constraints, which could limit the drug's availability and thus its market penetration. Additionally, British insurers' refusal to cover Wegovy could also limit its uptake, as it is priced significantly higher in the US compared to Europe.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100